DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Calan (Verapamil Hydrochloride) - Summary

 

-- advertisement --

CALAN SUMMARY

Calan®
verapamil hydrochloride tablets

Calan (verapamil HCl) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 40 mg, 80 mg, or 120 mg of verapamil hydrochloride.

Calan tablets are indicated for the treatment of the following:

Angina

  • Angina at rest including:
      —Vasospastic (Prinzmetal's variant) angina
    • —Unstable (crescendo, pre-infarction) angina
  • Chronic stable angina (classic effort-associated angina)
Arrhythmias

  • In association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and/or atrial fibrillation (see Warnings: Accessory bypass tract )
  • Prophylaxis of repetitive paroxysmal supraventricular tachycardia
Essential hypertension

CALAN NEWS HIGHLIGHTS

Published Studies Related to Calan (Verapamil)

Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). [2008.08]

Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. [2008.08]

Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy--a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil. [2007.11]

Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. [2007.08]

Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). [2007.06.01]

more>>

Clinical Trials Related to Calan (Verapamil)

Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg [Completed]

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg [Completed]

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg [Completed]

Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg [Completed]

The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers [Completed]

more>>

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008